DM2 is a metabolic disorder for which pioglitazone is available for its treatment, among its side effect is the weighted increase. Bioelectric bioimpedance is a technique that allows estimating the total body water percentage and body fat. Purpose: The relation between weight increase of patients with Type 2 Diabetes mellitus receibing pioglitazone as part of their treatment was evaluated. Methods: Longitudinal, observational, descriptive, comparative clinical trial performed at the UMF 80 in Morelia for 16 weeks during the period 2016-2017. Patients with DM2 were included, selected by random sampling by convenience, unspecified sex, but stable, forming 2 groups, one with pioglitazone treatment and the other with different anti-diabetics, anthropometric measurements were made and biochemical measurements were obtained; bioimpedance was performed. Data is expressed as, chi2 for the associations (p< 0.05 significance). Record number: R-2016-1603-15 Results. Forty patients were included. Experimental group: 20 subjects, 10 male (25%) and 10 female (25%) with an initial weight of 69.40±2.10 kg and final weight of 69.81±2.42 kg (p=.577), initial body fat %: 26.73±1.09 and final: 28.29±1.11(p=.043), initial body water %: 53.69±1.52 and final: 55.25±1.11 (p=.163), and a control group: 20 subjects, 10 males (25%) and 10 female (25%) with an initial weight of 75.72±2.94 kg and final of 75.10±3.17 kg (p=.435), initial body fat %: 30.77±1.53 y final: 31.59±1.66 (p=.081), initial body water %: 51.80±1.42 and final: 53.24±1.22 (p=.013). Conclusion. The expected weight increase was not observed by using pioglitazone. Key words: Pioglitazone. Weight. Diabetes Mellitus 2. bioimpedance bioelectrical. total body water percentage. body fat.
La DM 2 es una alteración metabólica que para su tratamiento tenemos disponible la pioglitazona, entre sus efectos adversos está el incremento ponderal. La bioimpedancia bioeléctrica es una técnica que permite la estimación del porcentaje agua corporal total y grasa corporal. Objetivo: Se evaluó la relación entre el incremento ponderal de los pacientes con Diabetes mellitus tipo 2 que reciben pioglitazona como parte de su tratamiento. Métodos: Estudio longitudinal, observacional, descriptivo, comparativo, cuasi experimental, realizado en la UMF 80 de Morelia durante 16 semanas en el periodo del 2016-2017. Se incluyeron pacientes con DM2, seleccionados mediante muestro no aleatorio, género indistinto, peso estable, formaron 2 grupos, a uno se inició tratamiento con pioglitazona y otro con tratamiento con diferentes antidiabéticos, realizaron mediciones antropométricas y capturaron mediciones bioquímicas; se les realizo bioimpedancia. Los datos se expresan en E E X . , chi2 para asociaciones (significanciap < 0.05). Número de registro: R-2016-1603-15 Resultados. Se incluyeron 40 pacientes,grupo experimental: 20 sujetos, 10 hombres (25%) y 10 mujeres (25%) con peso inicial de 69.40±2.10 kg y final de 69.81±2.42 kg (p=.577), % Grasa Corporal inicial: 26.73±1.09 y final: 28.29±1.11(p=.043), % Agua Corporal inicial: 53.69±1.52 y final: 55.25±1.11 (p=.163), y un grupo control: 20 sujetos, 10 hombres (25%) y 10 mujeres (25%) con peso inicial de 75.72±2.94 kg y final de 75.10±3.17 kg (p=.435), % Grasa Corporal inicial: 30.77±1.53 y final: 31.59±1.66 (p=.081), % Agua Corporal inicial: 51.80±1.42 y final: 53.24±1.22 (p=.013). Conclusión. No se encontró un incremento ponderal esperado con el uso de pioglitazona.
